Clinical trial NCT03265080 - References

Metastatic Melanoma — A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Citation(s)

•   Hecht JR, Goldman JW, Hayes S, Balli D, Princiotta MF, Dennie JG, Heyburn J, Sands T, Sheeri S, Petit R, Gutierrez AA, Tsai F
  Safety and immunogenicity of a personalized neoantigen -Listeria vaccine in cancer patients. AACR Annual Meeting 2019.
•   Hecht JR, Sheeri S, Heyburn J, Parsi M , Gutierrez AA, Tsai F
  Clinical and immunogenicity data of a personalized neoantigen-Listeria vaccine in cancer patients: preliminary results. IO Combinations 360. Philadelphia, PA 20 June 2019.
•   Tsai F, Goldman JW, Kosoff R, Heyburn JW, Sands T, Sheeri S, Petit R, Gutierrez AA, Hecht JR
  Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients. Frontiers in Cancer Immunotherapy, The New York Academy of Sciences,

A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

Details for clinical trial NCT03265080